Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study Comparing Sacituzumab Govitecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of lung cancer known as Non-Small Cell Lung Cancer (NSCLC). The study is comparing two treatments for patients with advanced or metastatic NSCLC who have experienced progression after receiving certain previous treatments. The two treatments being compared are Sacituzumab Govitecan and Docetaxel. Sacituzumab Govitecan is a type of medication known as an antibody drug conjugate, which is designed to target and kill cancer cells. Docetaxel is a chemotherapy drug that works by stopping cancer cells from growing and dividing.

The purpose of this study is to compare the overall survival of patients receiving Sacituzumab Govitecan versus those receiving Docetaxel. Patients participating in the study will be randomly assigned to receive one of these two treatments. The study will be conducted over a period of time, with patients receiving their assigned treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor patients to see how long they live after starting the treatment and will also look at other factors such as the progression of the disease and any side effects experienced.

This study is open-label, meaning both the patients and the researchers know which treatment is being administered. It is a global, multicenter study, which means it is being conducted in multiple locations around the world. The study aims to provide valuable information on the effectiveness and safety of Sacituzumab Govitecan compared to Docetaxel in treating advanced or metastatic NSCLC.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization

    Upon joining the study, you will be randomly assigned to receive either sacituzumab govitecan or docetaxel. This process is called randomization and ensures that each participant has an equal chance of receiving either treatment.

  2. Step 2

    Treatment administration

    If assigned to sacituzumab govitecan, you will receive it as a solution for infusion through a vein (intravenous use). The dosage is 200 mg, and it will be administered on specific days as determined by the study protocol.

    If assigned to docetaxel, you will receive it as a concentrate for solution for infusion through a vein (intravenous use). The dosage is 20 mg/1 ml, and it will be administered on specific days as determined by the study protocol.

  3. Step 3

    Monitoring and assessments

    Throughout the study, regular monitoring will occur to assess your health and the effectiveness of the treatment. This includes imaging tests like CT or MRI scans to measure the disease's response to treatment.

    Your health will be evaluated using various criteria, including the Eastern Cooperative Oncology Group (ECOG) performance status, which measures your ability to perform daily activities.

  4. Step 4

    Follow-up

    After completing the treatment phase, follow-up visits will be scheduled to continue monitoring your health and any long-term effects of the treatment.

    The study aims to compare overall survival (OS) between the two treatment groups, which is the time from randomization until death from any cause.

Who can join the trial?

11 criteria

  • Patients must have **non-small cell lung cancer** (NSCLC) that is at **Stage 4**, which means the cancer has spread to other parts of the body.
  • Patients must be **18 years of age or older** and able to understand and give written consent to participate in the study.
  • Patients must have a **life expectancy of 3 months or more**.
  • Patients must have **adequate liver function**, which means their liver is working well enough. This is checked by measuring certain substances in the blood, like bilirubin and liver enzymes.
  • Patients must have a **creatinine clearance** of at least 30 mL/min. This is a measure of how well the kidneys are working.
  • Patients must have **adequate blood counts** without needing blood transfusions or growth factor support within 2 weeks before starting the study drug. This includes having enough red blood cells, white blood cells, and platelets.
  • Patients must have **measurable disease** based on imaging tests like CT or MRI scans. This means the cancer can be seen and measured on these scans.
  • Patients must have an **ECOG performance status score of 0 or 1**. This is a scale that measures how well patients can perform daily activities, with 0 being fully active and 1 being restricted in physically strenuous activity but able to carry out light work.
  • Patients must have **progressed after certain treatments**. This means their cancer got worse after receiving specific therapies, such as platinum-based chemotherapy combined with anti-PD-1/PD-L1 antibody treatments.
  • Patients must have results for **EGFR, ALK, and PD-L1 tests** before joining the study. These are tests that look for specific changes in the cancer cells that might affect treatment options.
  • Male and female patients who can have children must agree to use specific methods of **contraception** to prevent pregnancy during the study.

Who cannot join the trial?

5 criteria

  • Patients with a different type of cancer other than non-small cell lung cancer cannot participate. This type of cancer affects the lungs and is not the same as small cell lung cancer.
  • Patients who are not within the specified age range cannot participate. The study is open to certain age groups only.
  • Patients who are not part of the specified clinical trial groups cannot participate. This means the study is looking for specific characteristics in participants.
  • Both male and female patients are eligible, so gender is not a reason for exclusion.
  • Patients who are considered part of a vulnerable population may not be eligible. This term refers to groups who might need special protection or care, such as children, pregnant women, or those with certain disabilities.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Sacituzumab Govitecan

    is a medication being studied for its effectiveness in treating advanced or metastatic non-small cell lung cancer. It is designed to target and deliver chemotherapy directly to cancer cells, potentially reducing the growth of tumors and improving patient outcomes.

  • Docetaxel

    is a chemotherapy drug commonly used to treat various types of cancer, including lung cancer. It works by interfering with the growth and division of cancer cells, which may help to slow down or stop the progression of the disease.

What is already known about the treatment

  • Sacituzumab Govitecan

    This medication is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating advanced or metastatic non-small cell lung cancer. It is an antibody-drug conjugate, which means it combines an antibody with a chemotherapy drug to target and kill cancer cells more effectively. Sacituzumab Govitecan works by binding to a protein called Trop-2 on the surface of cancer cells, delivering the chemotherapy directly to the tumor. It is classified as an antineoplastic agent, specifically designed to treat certain types of cancer.

  • Docetaxel

    This medication is also administered intravenously and is a well-established treatment for various types of cancer, including non-small cell lung cancer. It is a chemotherapy drug that belongs to the class of medications known as taxanes. Docetaxel works by interfering with the normal function of microtubules in cells, which are essential for cell division, thereby inhibiting the growth and spread of cancer cells. It is widely used in oncology and has been a standard treatment option for many years.

Investigated diseases

Non-small cell lung cancer – This is a type of lung cancer that includes several subtypes, such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. It is the most common type of lung cancer, accounting for about 85% of all cases. The disease typically begins in the tissues of the lungs and can spread to other parts of the body. Symptoms may include a persistent cough, chest pain, and difficulty breathing. As the disease progresses, it may lead to more severe respiratory issues and other systemic symptoms. The progression can vary significantly depending on the subtype and stage at diagnosis.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-512148-50-00Protocol codeGS-US-577-6153Estimated enrolment542 patientsSponsorGilead Sciences Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.